# NeuroPace

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuropace

- Industry: Medical Devices & Equipment
- Headquarters: Mountain View, US
- Website: www.neuropace.com
- Total disclosed funding: $123M
- Latest round: Series B (Aug 19, 2020)
- Investors on record: 12

## About

Based in the US, NeuroPace, Inc. specializes in innovative medical technology, particularly focused on providing advanced therapies for individuals experiencing drug-resistant epilepsy through its proprietary RNS® System platform.NeuroPace, Inc. was founded in 1999 and is headquartered in Mountain View, California, US. The company is dedicated to developing medical solutions for epilepsy management, having raised USD 102 mn through its IPO on April 21, 2021, valuing the company at USD 445 million. The IPO represents the entirety of the total funds raised to date, amounting to USD 102 mn. The CEO and co-founders are Joel Becker and Michael Favet, who have a strong background in medical device innovation.NeuroPace focuses on providing advanced medical solutions for drug-resistant epilepsy with its RNS® System. This system delivers personalized, real-time treatment directly at the source of seizures, tailored to patients' unique patterns, specifically for adults with up to two identified epileptogenic foci. The primary clientele consists of healthcare providers and patients across the United States, aimed at improving the quality of life through effective seizure management.In the most recent fiscal year 2024, NeuroPace recorded a revenue of USD 79.91 mn, with an EBITDA of USD -19.67 mn. The company earns income primarily from the direct sale of the RNS® System to healthcare providers, paired with ongoing service agreements for support and maintenance, emphasizing a direct-to-consumer model for patient access to innovative treatments.Following its IPO in April 2021, NeuroPace plans to utilize the raised USD 102 mn to enhance its product offerings and expand market reach. The company is focusing on developing additional features for the RNS® System and plans to target new geographic markets, particularly in Europe and Asia, by 2025. The funding will also support research partnerships with medical institutions to further epilepsy management and treatment innovation.

## Funding rounds

- Series B, Aug 19, 2020, $33M — OrbiMed Advisors, Accelmed, Revelation Partners, KCK Group, Soleus Capital
- Series A, Aug 7, 2017, $72M — OrbiMed Advisors, KCK Group
- Series I, Jun 30, 2013, $18M — Domain Associates, InterWest Partners, Kleiner Perkins, MedVenture Associates, New Enterprise Associates, Technology Venture Partners, Johnson & Johnson Innovation

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series I
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series I
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series I
- MedVenture Associates (https://capitalatlas.ai/funds/medventure-associates) — Series I
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series I
- Technology Venture Partners — Series I
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series I
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- KCK Group — Series A, Series B
- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series B
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series B
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B